In re: Tejidor, et al. Serial No.: 09/698,589 Filed: October 27, 2000

Page 2

9 (amended). The reagent of claim 8, wherein the phospholipids comprise all of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine and at a ratio of approximately from 1 to 10 mole percent phosphatidylserine and from about 5 to 30 mole percent phosphatidylethanolamine and the remainder phosphatidylcholine.

12 (amended). The reagent of claim 4, wherein the metal cation is a divalent metal cation selected from the group consisting of magnesium, calcium or manganese.

16 (amended). The reagent of claim 15, wherein the protein C activator is purified human thrombomodulin, purified non-human mammalian thrombomodulin, soluble or membrane associated thrombomodulin, native thrombomodulin or thrombomodulin reconstituted with phospholipids, partially or fully glycolsylated thrombomodulin, or fully deglycosylated thrombomodulin.

17 (amended). The reagent of claim 1, further comprising at least one member of the group consisting of buffers and stabilizers.

27 (amended). A reagent comprising: a coagulation activator at a concentration of 11 picomolar or less wherein said reagent may be utilized to assess a hypocoaguable, normal or hypercoaguable condition in a single assay.

31 (amended). The reagent of claim 27, wherein the reagent indicates a sample to be any of hypocoagulable, normal or hypercoagulable, depending upon the condition of the patient from which the sample was taken.

32 (amended). The reagent of claim 27, wherein the reagent indicates a patient, from which the sample was taken, to have any of thrombotic tendency, hemorraghic tendency, or stasis, depending on the patient.

35 (amended). The reagent of claim 34, wherein the phospholipids comprise all of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine and at a

6

Co

(M

O.B

In re: Tejidor, et al. Serial No.: 09/698,589 Filed: October 27, 2000 Page 3 ratio of approximately from 0 to 10 mole percent phosphatidylserine and from about mole percent phosphatidylethanolamine and the remainder phosphatidylcholine. 3λ (amended). The reagent of claim 30, wherein the metal cation is a divalent metal cation selected from the group consisting of magnesium, calcium or manganese. 42 (amended). The reagent of claim 27, further comprising at least one member selected from the group consisting of buffers and stabilizers. 83 (amended). The reagent of claim 16, wherein the thrombomodulin comprises heparin. 88 (amended). The reagent of claim 1, wherein said fibrin polymerization is preceded by an initiation phase, and wherein the coagulation activator detects defects in the initiation phase. 89 (amended). The reagent of claim 41, wherein the thrombomodulin comprises heparin. 94 (amended). The reagent of claim 27, wherein said coagulation activator is

present at a concentration level within a range sufficient to trigger a fibrin

polymerization, wherein said fibrin polymerization is preceded by an initiation phase,

and wherein the coagulation activator detects defects in the initiation phase.